



# The Royal College of Pathologists

## **NICE Appraisal Consultation Document (ACD): Second Consultation**

### **Cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy**

#### **Comments from The Royal College of Pathologists (RCPATH)**

The RCPATH welcomes the opportunity to comment on the second consultation. The feedback from the first consultation showed considerable agreement on the need to obtain better clinical outcome studies before being able to take a decision on the routine use of cinacalcet hydrochloride in secondary hyperparathyroidism. However, the feedback also showed strong support for the use of cinacalcet hydrochloride on an exceptional basis in severe and/or complicated cases where conventional therapy may not be indicated.

Against this background the RCPATH is pleased to see that the second consultation document has now recommended use of cinacalcet hydrochloride in patients with refractory secondary hyperparathyroidism who have very high serum PTH and in whom surgical parathyroidectomy is not indicated. The College sees this as a sensible step to take while waiting for more definitive clinical outcome studies. The College also supports the recommendation that the exceptional use of cinacalcet hydrochloride should not be allowed to continue if the serum PTH has not fallen by 30% within 3 months.